Want to see AU:PKY full AI Analyst Report?
Opyl Ltd. (PKY) AI Stock Analysis
Opyl Ltd.
(ASX:PKY)
The score is driven primarily by severe operating losses, persistent cash burn, and weak technical momentum. A debt-free balance sheet and substantial equity cushion provide some support, but negative earnings, negative cash flow, a negative P/E ratio, and absent dividend support keep the overall score near the bottom of the range.
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 21.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.19M
- Price to Earnings (P/E)
- -1.9
- Beta (1Y)
- 2.50
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Australia
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Opyl Ltd. Business Overview & Revenue Model
Company Description
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven so...
Opyl Ltd. Financial Statement Overview
Summary
Very weak revenue and persistent losses, combined with negative operating and free cash flow, indicate high financial risk. The debt-free balance sheet and approximately AUD 40m equity base provide meaningful support but do not offset the ongoing cash burn and lack of profitability.
Income Statement
12Very NegativeBalance Sheet
68PositiveCash Flow
28Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.63K | 47.63K | 27.78K | 397.64K | 397.64K | 617.91K |
| Gross Profit | -2.51M | -2.81M | -778.89K | -1.40M | -1.86M | -930.36K |
| EBITDA | -3.85M | -3.85M | -1.66M | -2.68M | -1.70M | -2.27M |
| Net Income | -3.65M | -3.65M | -1.45M | -3.13M | -3.13M | -1.73M |
Balance Sheet | ||||||
| Total Assets | 40.31M | 40.31M | 513.28K | 411.60K | 411.60K | 709.58K |
| Cash, Cash Equivalents and Short-Term Investments | 3.41M | 3.41M | 436.90K | 374.64K | 452.88K | 786.33K |
| Total Debt | 0 | 0 | 411.73K | 0 | 300.00K | 300.00K |
| Total Liabilities | 470.51K | 470.51K | 781.65K | 501.76K | 501.76K | 712.21K |
| Stockholders Equity | 39.84M | 39.84M | -268.37K | -90.16K | -403.59K | 267.01K |
Cash Flow | ||||||
| Free Cash Flow | -1.05M | -1.05M | -1.29M | -2.07M | -1.37M | -1.53M |
| Operating Cash Flow | -1.05M | -1.05M | -1.28M | -2.06M | -1.36M | -1.52M |
| Investing Cash Flow | -168.42K | -168.42K | -334.02K | -17.71K | -2,221 | -2,221 |
| Financing Cash Flow | 4.52M | 4.52M | 1.35M | 2.00M | 1.03M | 1.03M |
Opyl Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PKY, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 13.18 is Positive, neither overbought nor oversold. The STOCH value of 87.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PKY.
Opyl Ltd. Peers Comparison
Overall Rating
AU:CGS78Outperform
AU:ALC63Neutral
AU:ONE48Neutral
AU:BMT45Neutral
AU:AHE42Neutral
AU:PKY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | AUD 595.56M | 34.92 | 21.61% | 1.74% | 6.95% | 10.77% | |
| 63Neutral | AUD 148.48M | 64.70 | 2.53% | ― | 26.61% | 41.67% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | AUD 109.10M | -6.40 | -203.69% | ― | -1.53% | 28.29% | |
| 45Neutral | AUD 21.26M | -1.14 | -58.13% | ― | 2.08% | -195.31% | |
| 42Neutral | AUD 8.93M | -0.45 | -614.15% | ― | -46.09% | 70.70% | |
| 38Underperform | AUD 21.63M | -1.93 | -18.10% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:PKY | Opyl Ltd. | 0.02 | 0.00 | 0.00% | |
| AU:CGS | Cogstate Ltd | 3.45 | 0.66 | 23.52% | |
| AU:ONE | Oneview Healthcare PLC Chess Depository Interests repr 1 | 0.13 | -0.06 | -31.58% | |
| AU:BMT | Beamtree Holdings Ltd | 0.07 | -0.15 | -67.27% | |
| AU:AHE | MedAdvisor Limited | 0.01 | -0.01 | -46.15% | |
| AU:ALC | Alcidion Group Limited | 0.11 | 0.02 | 22.22% |
Opyl Ltd. Corporate Events
PathKey.AI Sets November AGM to Review 2026 Results and Executive Pay
PathKey.AI Ltd has convened its Annual General Meeting for 5 November 2026 in West Perth, where shareholders will review the company’s Annual Report for the year ended 30 June 2026, including financial statements, directors’ report and th...
Pathkey.AI sets AGM date and deadline for director nominations
Pathkey.AI Ltd has scheduled its Annual General Meeting for 29 October 2026, where the election and re-election of directors will be on the agenda. The company has set 23 September 2026 as the deadline for receiving director nominations at its regist...
Pathkey.AI Forms Advisory Board to Drive Chipforge Commercialisation
Pathkey.AI Ltd has established an Advisory Board to accelerate the build-out and commercialisation of its recently acquired Chipforge AI-native semiconductor design platform. The inaugural appointment is Associate Professor Anupam Chattopadhyay of Na...
Pathkey.AI Issues New ASX-Listed Shares Under Disclosure Exemption
Pathkey.AI Ltd has issued 1,150,000 fully paid ordinary shares on 4 September 2026, identified on the ASX under code PKY, without a prospectus or other disclosure document under the capital-raising provisions of the Corporations Act.The board-approve...
PathKey.AI Seeks ASX Quotation for New Share Issue
PathKey.AI has applied to the ASX for quotation of 1,150,000 new ordinary fully paid shares under its existing PKY code. The securities, issued on 4 September 2026, arise from the exercise or conversion of options or other convertible instruments, mo...
Pathkey.AI details corporate structure and ASX listing information
Pathkey.AI Ltd has outlined its key corporate directory details, including its board composition, company secretary, and principal place of business in Sydney. The release also confirms its share registry, auditor, and ASX listing information, reinfo...
Pathkey.AI Widens Loss Despite Revenue Surge and Chipforge Acquisition
Pathkey.AI Ltd reported a 71.4% rise in revenue to $47,632 for the year ended 30 June 2026, but its net loss widened 152.3% to $3.65 million, with no dividends declared. The group’s net tangible assets per share improved to 0.26 cents from nega...
Pathkey.AI issues new shares under streamlined disclosure provisions
Pathkey.AI Ltd has issued 7,452,380 fully paid ordinary shares on 20 August 2026, and has notified the market that these securities were issued without a prospectus or other disclosure document under the relevant capital-raising provisions of the Cor...
Pathkey.ai Seeks ASX Quotation for Over 5.4 Million New Shares
Pathkey.ai Ltd, an artificial intelligence-focused technology company listed on the ASX under the code PKY, provides investors with exposure to the growth of AI and data-driven solutions. Its ordinary fully paid shares are the primary vehicle through...
Pathkey.AI Seeks ASX Quotation for 2 Million New Shares
Pathkey.AI Ltd has applied for the quotation of 2,000,000 ordinary fully paid shares on the Australian Securities Exchange, with the securities issued on August 20, 2026. The move expands the company’s listed capital base, potentially enhancing...
Pathkey.ai Issues 21.8 Million Unquoted Options
Pathkey.ai Ltd has notified the ASX of the issue of 21,800,000 unquoted options, all classified under the PKYAA security code and expiring on various dates at various exercise prices. The options, which are not intended to be quoted, form part of pre...
PATHKEY.AI Issues 10 Million Unquoted Options to Support Capital Strategy
LTD PATHKEY.AI has notified the market of the issuance of 10,000,000 unquoted options, each exercisable at $0.05 and expiring on 17 December 2027. The options, recorded under ASX security code PKYAE, form part of previously announced transactions and...
Pathkey.AI Issues 100 Million New Shares in ASX-Compliant Placement
Pathkey.AI Ltd has issued 100,000,000 fully paid ordinary shares on 20 August 2026, notifying the market that this capital raising was conducted without a prospectus or other disclosure document under the Corporations Act. The company affirms it is c...
Pathkey.ai Seeks ASX Quotation for 100 Million Ordinary Shares
Pathkey.ai Ltd has lodged an application with the ASX for the quotation of 100,000,000 ordinary fully paid shares under the code PKY, with an issue date of 20 August 2026. The move formalises the company’s capital structure on the exchange and...
Pathkey.AI Director Damon Rasheed Lifts Indirect Shareholding
Non-executive director Damon Rasheed has increased his indirect shareholding in Pathkey.AI Ltd through an on-market purchase. Rasheed, via controlled entity DR Globalex Pty Ltd, acquired 200,000 ordinary shares for $7,600, adding to his existing mix...
PathKey.ai Plans Issue of 40 Million Performance Rights on ASX
PathKey.ai Ltd has notified the ASX of a proposed issue of up to 40 million performance rights under its PKYAAA class. The securities are to be issued via a placement or other structured issuance, with a proposed issue date of 20 August 2026.The move...
PathKey.ai Plans Large ASX Share Placement to Raise Capital
PathKey.ai Ltd has notified the ASX of a proposed placement of up to 100,000,000 ordinary fully paid shares, with a planned issue date of 20 August 2026. The company has applied for quotation of the new securities in accordance with ASX listing rules...
Pathkey.AI Brings In Former Altium Chair Sam Weiss and Secures $2.8m Placement
Pathkey.AI has appointed former Altium Limited chairman Sam Weiss as strategic advisor to its CEO and Chipforge team, leveraging his experience in scaling design software into a global leader and his insight into the convergence of electronic design...
Chipforge Wins First Commercial Contract Ahead of AI Chip Platform Launch
Pathkey.AI’s chip design subsidiary Chipforge has secured its first commercial customer contract ahead of the general release of its AI-native Chipforge platform, marking the company’s initial revenue from the technology. The deal is with...
Pathkey.AI Shares Halted Ahead of Capital Raising Announcement
Pathkey.AI Ltd has requested and received a trading halt on its securities from the ASX, effective 10 August 2026, while it prepares a market announcement. The halt will remain in place until either the release of the announcement or the resumption o...
Pathkey.AI accelerates AI chip design with Chipforge acquisition and expands TrialKey revenues
Pathkey.AI has completed the acquisition of Singapore-based Chipforge, integrating its AI-powered platform that turns high-level design intent into verified hardware code, significantly compressing traditional chip development cycles and supporting s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026